TY - JOUR
T1 - Impact of drusen burden on incidence of subclinical CNV with OCTA
AU - Uchida, Atsuro
AU - Srivastava, Sunil K.
AU - Manjunath, Deepa
AU - Singh, Rishi P.
AU - Rachitskaya, Aleksandra V.
AU - Kaiser, Peter K.
AU - Reese, Jamie L.
AU - Ehlers, Justis P.
N1 - Funding Information:
Originally submitted March 24, 2019. Revision received June 8, 2019. Accepted for publication July 29, 2019. Presented at the ARVO Annual Meeting, May 7-11, 2017. Supported by the Betty J. Powers Retina Research Fellowship (AU); an unrestricted travel grant from Alcon Novartis Hida Memorial Award 2015 funded by Alcon Japan Ltd. (AU); NIH/NEI K23-EY022947-01A1 (JPE); and Research to Prevent Blindness (Cole Eye Institutional Grant). Dr. Srivastava has received grants from Allergan, has a patent through Bioptigen/Leica, and has received personal fees from Zeiss, Bausch + Lomb, and Santen outside the submitted work. Dr. Singh has received personal fees from Zeiss, Genentech, Regeneron, and Alcon outside the submitted work. Dr. Rachitskaya has received personal fees from Allergan outside the submitted work. Dr. Kaiser has received personal fees from Zeiss, Regeneron, Alcon, Novartis, Bayer, Neurotech, Bausch + Lomb, and Topcon outside the submitted work. Dr. Ehlers reports grants from the NIH during the conduct of the study, in addition to personal fees from Leica, Aerpio, and Allegro; grants and personal fees from Novartis, Alcon, Thrombogenics, Genentech; and grants from Regeneron outside the submitted work. The remaining authors report no relevant financial disclosures. Dr. Singh did not participate in the editorial review of this manuscript. Address correspondence to Justis P. Ehlers, MD, Norman C. and Donna L. Harbert Endowed Chair for Ophthalmic Research, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Ave/i32, Cleveland, OH 44195; email: ehlersj@ccf.org. doi: 10.3928/23258160-20191211-03
Publisher Copyright:
© 2020 Slack Incorporated. All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - BACKGROUND AND OBJECTIVE: To evaluate the impact of drusen burden on the detection of subclinical choroidal neovascularization (CNV) on optical coherence tomography angiography (OCTA) in nonexudative age-related macular degeneration (AMD). PATIENTS AND METHODS: A subanalysis of the AVATAR study, subjects diagnosed with nonexudative AMD without subfoveal atrophy were included. Subclinical CNV was assessed using OCTA software, and drusen burden was graded utilizing the advanced retinal pigment epithelium (RPE) analysis. RESULTS: Among eligible 58 eyes, 26 eyes (45%) had high drusen burden. Of the three eyes (5%) that demonstrated subclinical CNV, only one eye had high drusen burden, and all three eyes had neovascular AMD in the fellow eye. Extrafoveal RPE atrophy (odds ratio [OR] = 20.0; 95% confidence interval [CI], 1.53-261) and older age (OR = 1.27; 95% CI, 1.01-1.59) were predictive factors for subclinical CNV. CONCLUSION: Extrafoveal RPE atrophy, older age, and fellow-eye CNV were significant risk factors for underlying subclinical CNV in nonexudative AMD.
AB - BACKGROUND AND OBJECTIVE: To evaluate the impact of drusen burden on the detection of subclinical choroidal neovascularization (CNV) on optical coherence tomography angiography (OCTA) in nonexudative age-related macular degeneration (AMD). PATIENTS AND METHODS: A subanalysis of the AVATAR study, subjects diagnosed with nonexudative AMD without subfoveal atrophy were included. Subclinical CNV was assessed using OCTA software, and drusen burden was graded utilizing the advanced retinal pigment epithelium (RPE) analysis. RESULTS: Among eligible 58 eyes, 26 eyes (45%) had high drusen burden. Of the three eyes (5%) that demonstrated subclinical CNV, only one eye had high drusen burden, and all three eyes had neovascular AMD in the fellow eye. Extrafoveal RPE atrophy (odds ratio [OR] = 20.0; 95% confidence interval [CI], 1.53-261) and older age (OR = 1.27; 95% CI, 1.01-1.59) were predictive factors for subclinical CNV. CONCLUSION: Extrafoveal RPE atrophy, older age, and fellow-eye CNV were significant risk factors for underlying subclinical CNV in nonexudative AMD.
UR - http://www.scopus.com/inward/record.url?scp=85077869159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077869159&partnerID=8YFLogxK
U2 - 10.3928/23258160-20191211-03
DO - 10.3928/23258160-20191211-03
M3 - Article
C2 - 31935299
AN - SCOPUS:85077869159
VL - 51
SP - 22
EP - 30
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
SN - 2325-8160
IS - 1
ER -